Table 3. Univariate survival analysis.

Characteristic	Categories	Patients(no)	Survival median (months)	1-year (%)	Logrank P
Age (years)	<60	215	9	29	0.235
	Δ60	135	11	39
Gender	Female	72	11	42	0.390
	Male	278	9	30
Performance status (WHO)	0	66	12	45	<0.001a
	1	219	10	35
	2	63	5	13
Weight loss (%)	Ω 5	121	12	39	0.006a
	5–10	91	9	32
	Δ 10	131	9	29
Tumor type	SCC	199	9	32	0.550
	Adenoca	145	10	32
Tumor differentiationb	Well/moderate	119	10	43	0.102
	Poor	131	9	28
Liver metastasis	No	269	10	37	<0.001
	Yes	81	7	21
No. of metastatic sites	0	42	10	36	0.02a
	1	190	10	34
	>1	118	7	31
Extent of disease	Locoregional	42	10	36	< 0.001c
	Limited dissem.	138	12	41	< 0.001c
	Extensive dissem.	170	7	26
Interval between diagnosis and start treatment	<6 months	295	10	34	0.65
	>6 months	55	8	27
Haemoglobin	Normal	228	10	36	0.253
	Abnormal	122	9	28
Alkaline phosphatase	Normal	246	10	37	0.001
	Elevated	104	7	24
LDH	Normal	296	11	46	<0.001
	Elevated	54	8	16
Paclitaxel	Yes	139	10	40	0.002
	No	211	9	29

^aTrend test,

^btumour differentiation was unknown in 100 patients,

^cvs extended dissemination.